Barclays Maintains Overweight on Ascendis Pharma, Raises Price Target to $341
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $329 to $341.
Follow the latest Ascendis Pharma A/S (ASND) news and market headlines alongside the live ASND price. Stay informed on what's moving ASND.
Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $329 to $341.
UBS analyst Joon Lee maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $269 to $315.
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $326 to $330.
RBC Capital analyst Luca Issi reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $290 price target.
TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $341 to $352.
Evercore ISI Group analyst Josh Schimmer maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $326 to $356.
Cantor Fitzgerald analyst Li Watsek maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $300 to $315.
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $344 to $335.
Ascendis Pharma (NASDAQ:ASND) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.97 per share which beat the analyst consensus estimate of $1.13 by 74.34 percent. This is a 328.26 percent increase over earnings of $0.46 per share from
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ASND, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.